By mitigating the degeneration and inflammatory response of motor neurons, NeuroSense reasons, PrimeC can improve motor performance, and recover the morphology of motor neurons, neuromuscular junction structures, and microglial cells—results first seen in preclinical studies in zebrafish models of ALS. Last year, NeuroSense reported positive results from its Phase IIa NST002 trial (NCT04165850) showing that PrimeC was both safe and tolerable in 15 ALS patients studied over 12 months . . .

Get GEN Edge Today!

See More on the Edge

Continue reading this article and more
with a GEN Edge subscription

Start Your 30-Day Free Trial Now

Log In Join GEN Edge